Triple
T1169602
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Ionis Pharmaceuticals |
E24882
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object | Spinraza |
E24879
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Spinraza | Statement: [Ionis Pharmaceuticals, notableProduct, Spinraza]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Spinraza Context triple: [Ionis Pharmaceuticals, notableProduct, Spinraza]
-
A.
Spinraza
chosen
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
C.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a494082a7c819095004f423f294a64 |
completed | March 1, 2026, 7:31 p.m. |
| NER | Named-entity recognition | batch_69a4bce821b481908bc278a3fa7973f4 |
completed | March 1, 2026, 10:25 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac8311ba6481908aaca4c1e9d8b78f |
completed | March 7, 2026, 7:57 p.m. |
Created at: March 1, 2026, 7:45 p.m.